Try
Johnson & Johnson
JNJUnited States
71 filed reports · 724 financial concepts · 42 earnings calls · 37 media appearances
Filed reports
71 reports · Jul 2016 to Jul 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 351 guidance figures, 6 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 16,555 | Jul 2016 to Jun 2026 |
| Current · 8-KSEC EDGAR | 30 | 420 | Sep 2019 to Jul 2026 |
| Annual · 10-KSEC EDGAR | 10 | 12,619 | Jan 2017 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2027 Q2 | 8-K | Jul 31, 2026 | Oct 13, 2026 | 12 | Open |
| FY2027 Q2 | 10-Q | Jun 28, 2026 | Jul 23, 2026 | 913 | Open |
| FY2027 Q2 | 8-K | Jun 28, 2026 | Jul 15, 2026 | 18 | Open |
| FY2027 Q1 | 10-Q | Mar 29, 2026 | Apr 22, 2026 | 788 | Open |
| FY2027 Q1 | 8-K | Mar 29, 2026 | Apr 14, 2026 | 8 | Open |
| FY2026 | 10-K | Dec 28, 2025 | Feb 11, 2026 | 2,481 | Open |
| FY2026 Q4 | 8-K | Dec 28, 2025 | Jan 21, 2026 | 4 | Open |
| FY2026 Q3 | 10-Q | Sep 28, 2025 | Oct 22, 2025 | 817 | Open |
| FY2026 Q3 | 8-K | Sep 28, 2025 | Oct 14, 2025 | 8 | Open |
| FY2026 Q2 | 10-Q | Jun 29, 2025 | Jul 24, 2025 | 528 | Open |
| FY2026 Q2 | 8-K | Jun 29, 2025 | Jul 16, 2025 | 6 | Open |
| FY2026 Q1 | 10-Q | Mar 30, 2025 | Apr 23, 2025 | 521 | Open |
Financial data
724 concepts · 29,594 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Segment64 concepts · 16,555 facts · Dec 2014 to Jun 2026
- Revenue9,469 · Dec 2014 to Jun 2026
- U.S.5,508 · Jul 2016 to Jun 2026
- Goodwill145 · Jan 2016 to Jun 2026
- Goodwill acquired during period137 · Jan 2016 to Jun 2026
- Goodwill other increase decrease122 · Jan 2017 to Jun 2026
- Restructuring charges111 · Jan 2016 to Jun 2026
- Operating income loss89 · Jun 2015 to Sep 2024
- Adjustment for amortization84 · Apr 2017 to Jun 2026
- Depreciation depletion and amortization82 · Dec 2014 to Jun 2026
- Goodwill written off related to sale of business unit81 · Jan 2016 to Jun 2026
- Litigation settlement expense74 · Dec 2014 to Dec 2025
- Percentage Change in Operating Income Loss65 · Jul 2016 to Sep 2024
- Total Assets63 · Jan 2016 to Jun 2026
- Segment expenditure addition to long lived assets50 · Jan 2022 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest38 · Dec 2019 to Jun 2026
- Property plant and equipment additions38 · Dec 2014 to Jan 2023
- Cost of goods and services sold (US GAAP)28 · Jan 2023 to Jun 2026
- Other nonoperating income expense28 · Jan 2023 to Jun 2026
- Research and development expense excluding acquired in process cost28 · Jan 2023 to Jun 2026
- Selling general and administrative expense28 · Jan 2023 to Jun 2026
- Income loss from continuing operations before income taxes minority interest and income loss from equity method investments21 · Dec 2014 to Jan 2021
- Business combination acquisition related costs20 · Oct 2017 to Jun 2026
- Research and development in process20 · Dec 2014 to Jan 2022
- Depreciation & Amortization18 · Jan 2016 to Mar 2026
Financial616 concepts · 12,088 facts · Dec 2014 to Jul 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Gross profit (US GAAP)58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Investment income interest57 · Dec 2014 to Jun 2026
- Less: shares which could be repurchased under treasury stock method57 · Dec 2014 to Jun 2026
- Other comprehensive income foreign currency transaction and translation gain loss before reclassification and tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss net of tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss pension and other postretirement benefit plans adjustment net of tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss pension and other postretirement benefit plans tax57 · Dec 2014 to Jun 2026
- Other nonoperating income expense57 · Dec 2014 to Jun 2026
- Research and development expense excluding acquired in process cost57 · Dec 2014 to Jun 2026
- Restructuring charges57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Amortization of intangible assets56 · Dec 2014 to Jun 2026
- Asset impairment charges56 · Dec 2014 to Jun 2026
- Deferred income tax expense benefit56 · Dec 2014 to Jun 2026
- Depreciation depletion and amortization56 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities56 · Dec 2014 to Jun 2026
- Increase decrease in accounts receivable56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Increase decrease in other operating assets56 · Dec 2014 to Jun 2026
- Increase decrease in other operating liabilities56 · Dec 2014 to Jun 2026
Geography3 concepts · 516 facts · Dec 2014 to Jun 2026
- Revenue318 · Dec 2014 to Jun 2026
- U.S.175 · Jul 2016 to Jun 2026
- Revenue (excluding assessed tax)23 · Dec 2019 to Dec 2025
Guidance38 concepts · 420 facts · Oct 2019 to Oct 2026
- Revenue Guidance44 · Oct 2019 to Oct 2026
- Revenue Growth Guidance40 · Oct 2019 to Jul 2026
- EPS (Diluted) Growth Guidance (Adjusted (non-GAAP))34 · Oct 2019 to Oct 2026
- EPS (Diluted) Guidance (Adjusted (non-GAAP))34 · Oct 2019 to Oct 2026
- EPS (Diluted) Growth Guidance (Adjusted, constant currency)32 · Oct 2019 to Jul 2026
- EPS (Diluted) Guidance (Adjusted, constant currency)32 · Oct 2019 to Jul 2026
- Revenue Growth Guidance (Constant currency)24 · Oct 2019 to Oct 2026
- Revenue Guidance (Constant currency)24 · Oct 2019 to Oct 2026
- EPS (Diluted) Guidance20 · Oct 2020 to Apr 2026
- Revenue Growth Guidance (Organic, constant currency)14 · Jul 2020 to Oct 2026
- EPS (Diluted) Growth Guidance12 · Jan 2022 to Apr 2026
- Revenue Growth Guidance (Adjusted, constant currency)10 · Oct 2019 to Jul 2026
- Revenue Growth Guidance (Excludes COVID-19 Vaccine)6 · Jul 2022 to Jan 2023
- Revenue Growth Guidance (Excludes COVID-19 Vaccine; Constant currency)6 · Jul 2022 to Jan 2023
- Revenue Growth Guidance (Excludes COVID-19 Vaccine; Organic, constant currency)6 · Jul 2022 to Jan 2023
- Revenue Guidance (Excludes COVID-19 Vaccine)6 · Jul 2022 to Jan 2023
- Revenue Guidance (Excludes COVID-19 Vaccine; Constant currency)6 · Jul 2022 to Jan 2023
- EPS (Diluted) Guidance (incl. COVID Vx; Adjusted, constant currency)4 · Jul 2021 to Oct 2021
- EPS (Diluted) Guidance (incl. COVID Vx; Adjusted (non-GAAP))4 · Jul 2021 to Oct 2021
- Revenue Growth Guidance (Base Business)4 · Jul 2021 to Oct 2021
- Revenue Growth Guidance (base business; Constant currency)4 · Jul 2021 to Oct 2021
- Revenue Growth Guidance (excluding COVID-19 Vaccine)4 · Jul 2023 to Apr 2024
- Revenue Growth Guidance (excluding COVID-19 Vaccine; Organic, constant currency)4 · Jul 2023 to Apr 2024
- Revenue Growth Guidance (incl. COVID Vx)4 · Jul 2021 to Oct 2021
Product3 concepts · 15 facts · Dec 2017 to Dec 2025
- Cost of goods and services sold (US GAAP)6 · Dec 2017 to Jan 2023
- Loss contingency accrual payments5 · Apr 2023 to Dec 2023
- Selling general and administrative expense4 · Jan 2022 to Dec 2025
Segments
17,086 factsFigures broken down by business line, region, product or another axis the company reports on.
Subsegments21 members · 12,923 facts
- Oncology1,954 · Jan 2017 to Jun 2026
- Immunology1,743 · Jan 2017 to Jun 2026
- Neuroscience1,502 · Jan 2017 to Jun 2026
- Orthopaedics1,425 · Jan 2017 to Jun 2026
- Infectious Diseases1,282 · Jan 2017 to Jun 2026
- Pulmonary Hypertension1,203 · Jan 2017 to Jun 2026
- Cardiovascular Metabolism Other1,189 · Jan 2017 to Jun 2026
- Surgery951 · Jan 2017 to Jun 2026
- Vision825 · Jan 2017 to Jun 2026
- Interventional Solutions248 · Jan 2017 to Dec 2023
- Cardiovascular159 · Jan 2023 to Jun 2026
- Electrophysiology81 · Apr 2022 to Jun 2026
- Diabetes Care77 · Jan 2017 to Dec 2019
- Abiomed72 · Apr 2022 to Jun 2026
- Other Cardiovascular57 · Apr 2023 to Jun 2026
- Diagnostics44 · Jan 2017 to Dec 2019
- Shockwave40 · Jul 2023 to Jun 2026
- Other Interventional Solutions27 · Apr 2022 to Oct 2023
- Vision Care24 · Apr 2017 to Apr 2018
- Total PHIDCVM18 · Mar 2025 to Jun 2026
- OPSUMIT2 · Dec 2019
Statement business segments19 members · 3,632 facts
- Consumer1,588 · Dec 2014 to Dec 2025
- Pharmaceutical523 · Dec 2014 to Oct 2023
- Medical Devices511 · Dec 2014 to Jul 2023
- Med Tech350 · Jan 2021 to Jun 2026
- Innovative Medicine331 · Jan 2022 to Jun 2026
- Pharmaceutical60 · Jan 2016 to Dec 2025
- Consumer46 · Jan 2016 to Jul 2023
- Segments Total46 · Dec 2014 to Jun 2026
- Medical devices45 · Jan 2016 to Jul 2023
- Segments total35 · Jan 2016 to Mar 2026
- Med tech30 · Jan 2022 to Jun 2026
- Innovative medicine26 · Jan 2023 to Jun 2026
- Medical Devices And Diagnostics20 · Mar 2015 to Dec 2019
- Med Tech Surgery Franchise8 · Jun 2024 to Jun 2026
- CONSUMERHEALTH And PHARMACEUTICAL6 · Jan 2021 to Jan 2022
- Medtech Surgery Franchise3 · Dec 2023 to Dec 2025
- Consumer Health2 · Jan 2023
- Actelion1 · Apr 2018
- Orthopaedics Restructuring Plan1 · Dec 2025
Statement geographicalsrt:StatementGeographicalAxis5 members · 345 facts
- Non Us74 · Dec 2017 to Jun 2026
- US74 · Dec 2017 to Jun 2026
- Asia Pacific Africa66 · Dec 2017 to Jun 2026
- Europe66 · Dec 2017 to Jun 2026
- Western Hemisphere Excluding US65 · Dec 2017 to Jun 2026
Statement geographicalus-gaap:StatementGeographicalAxis12 members · 171 facts
- US30 · Dec 2014 to Dec 2018
- Asia Pacific Africa28 · Dec 2014 to Dec 2018
- Europe28 · Dec 2014 to Dec 2018
- Western Hemisphere Excluding US28 · Dec 2014 to Dec 2018
- Non Us19 · Oct 2016 to Dec 2018
- International11 · Jun 2015 to Jul 2017
- Asia pacific africa7 · Dec 2019 to Dec 2025
- Western hemisphere excluding us7 · Dec 2019 to Dec 2025
- Europe7 · Dec 2019 to Dec 2025
- Segments Total4 · Dec 2014 to Dec 2017
- Us1 · Jan 2022
- Non us1 · Jan 2022
Product or service2 members · 15 facts
- Shipping And Handling10 · Dec 2017 to Dec 2025
- Opioid5 · Apr 2023 to Dec 2023
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary92 claims from 9 reports · Sep 2024 to Jul 2026
- Management discussion (MD&A) commentary220 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes3 claims from 1 reports · Dec 2025
- Risk factors53 risks from 2 annual reports · 2025 to 2026
Earnings calls
42 calls · Jul 2016 to Oct 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q3Oct 13, 2026
- FY2026 Q2Jul 15, 2026
- FY2026 Q1Apr 14, 2026
- FY2025 Q4Jan 21, 2026
- FY2025 Q3Oct 14, 2025
- FY2025 Q2Jul 16, 2025
- FY2025 Q1Apr 15, 2025
- FY2024 Q4Jan 22, 2025
- FY2024 Q3Oct 15, 2024
- FY2024 Q2Jul 17, 2024
- FY2024 Q1Apr 16, 2024
- FY2023 Q4Jan 23, 2024
- FY2023 Q3Oct 17, 2023
- FY2023 Q2Jul 20, 2023
- FY2023 Q1Apr 18, 2023
- FY2022 Q4Jan 24, 2023
Executive media
37 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews25 · Oct 2019 to Oct 2025
- Other appearances8 · Aug 2023 to Oct 2026
- Conference talks2 · Jan 2024 to Jan 2026
- Podcasts2 · Mar 2021 to Oct 2026
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.